MX2023006842A - Proceso de fabricacion e intermediarios para un compuesto de pirrolo[2,3-d]pirimidina y su uso. - Google Patents
Proceso de fabricacion e intermediarios para un compuesto de pirrolo[2,3-d]pirimidina y su uso.Info
- Publication number
- MX2023006842A MX2023006842A MX2023006842A MX2023006842A MX2023006842A MX 2023006842 A MX2023006842 A MX 2023006842A MX 2023006842 A MX2023006842 A MX 2023006842A MX 2023006842 A MX2023006842 A MX 2023006842A MX 2023006842 A MX2023006842 A MX 2023006842A
- Authority
- MX
- Mexico
- Prior art keywords
- pyrrolo
- intermediates
- manufacturing process
- pyrimidine compound
- crystalline form
- Prior art date
Links
- 239000000543 intermediate Substances 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- -1 pyrrolo[2,3- d]pyrimidine compound Chemical class 0.000 title 1
- IUEWXNHSKRWHDY-UHFFFAOYSA-N N-[3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl]propane-1-sulfonamide Chemical compound C1C(NS(=O)(=O)CCC)CC1N(C)C1=NC=NC2=C1C=CN2 IUEWXNHSKRWHDY-UHFFFAOYSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
Abstract
Un proceso de fabricación de intermediarios para preparar una forma cristalina o no cristalina de N-((1S,3S)-3-(metil(7H-pirrolo [2,3-d]pirimidin-4-il)amino)ciclobutil)propan-1-sulfonamida; formas de sal y composiciones farmacéuticas que comprenden la forma cristalina, y métodos para el uso del compuesto preparado de una forma cristalina en el tratamiento de diversas enfermedades.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862694698P | 2018-07-06 | 2018-07-06 | |
US201862776642P | 2018-12-07 | 2018-12-07 | |
US201962855071P | 2019-05-31 | 2019-05-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2023006842A true MX2023006842A (es) | 2023-06-22 |
Family
ID=67928862
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020013896A MX2020013896A (es) | 2018-07-06 | 2019-07-03 | Proceso de fabricacion e intermediarios para un compuesto de pirrolo[2,3-d]pirimidina y su uso. |
MX2023006842A MX2023006842A (es) | 2018-07-06 | 2020-12-16 | Proceso de fabricacion e intermediarios para un compuesto de pirrolo[2,3-d]pirimidina y su uso. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020013896A MX2020013896A (es) | 2018-07-06 | 2019-07-03 | Proceso de fabricacion e intermediarios para un compuesto de pirrolo[2,3-d]pirimidina y su uso. |
Country Status (13)
Country | Link |
---|---|
US (3) | US10815240B2 (es) |
EP (1) | EP3817810A1 (es) |
JP (1) | JP7437646B2 (es) |
KR (1) | KR102568464B1 (es) |
CN (1) | CN112384282A (es) |
AU (1) | AU2019299666A1 (es) |
BR (1) | BR112020025701A2 (es) |
CA (1) | CA3105161C (es) |
IL (1) | IL279926B2 (es) |
MX (2) | MX2020013896A (es) |
TW (1) | TWI709562B (es) |
WO (1) | WO2020008391A1 (es) |
ZA (1) | ZA202100196B (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3969458A4 (en) | 2019-05-13 | 2023-05-17 | Borah, Inc. | CHEMICAL COMPOUNDS |
CN113637018A (zh) | 2020-04-27 | 2021-11-12 | 苏州晶云药物科技股份有限公司 | 磺酰胺类化合物的晶型及其制备方法 |
CN112279785B (zh) * | 2020-10-29 | 2022-08-16 | 苏利制药科技江阴有限公司 | 3,3-二氟环丁胺盐酸盐中间体及其合成方法和3,3-二氟环丁胺盐酸盐合成方法 |
CN113583992B (zh) * | 2021-07-15 | 2023-06-27 | 华东理工大学 | 一种还原胺化酶及其在仲胺合成中的应用 |
WO2023036289A1 (zh) * | 2021-09-10 | 2023-03-16 | 上海海和药物研究开发股份有限公司 | 具有enpp1抑制活性的异羟基肟酸类化合物及其用途 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
JP4126781B2 (ja) | 1998-10-26 | 2008-07-30 | 宇部興産株式会社 | 1−スルホニルピラゾール誘導体及びその製造方法 |
JP2003005323A (ja) | 2001-06-20 | 2003-01-08 | Konica Corp | 熱現像写真感光材料及び画像形成方法 |
GB0710528D0 (en) | 2007-06-01 | 2007-07-11 | Glaxo Group Ltd | Novel compounds |
SG10201600910YA (en) | 2009-08-10 | 2016-03-30 | Bhi Ltd Partnership | Methods, compounds, and compositions for delivering 1,3-propanedisulfonic acid |
AR087072A1 (es) | 2011-07-08 | 2014-02-12 | Syngenta Participations Ag | Procesos para la preparacion de tietanamina |
JP6145179B2 (ja) | 2013-02-22 | 2017-06-07 | ファイザー・インク | ヤヌス関連キナーゼ(JAK)の阻害剤としてのピロロ[2,3−d]ピリミジン誘導体 |
JP6585158B2 (ja) | 2014-08-12 | 2019-10-02 | ファイザー・インク | ヤヌスキナーゼの阻害に有用なピロロ[2,3−d]ピリミジン誘導体 |
-
2019
- 2019-07-03 CA CA3105161A patent/CA3105161C/en active Active
- 2019-07-03 TW TW108123441A patent/TWI709562B/zh active
- 2019-07-03 AU AU2019299666A patent/AU2019299666A1/en active Pending
- 2019-07-03 CN CN201980045496.5A patent/CN112384282A/zh active Pending
- 2019-07-03 US US16/502,703 patent/US10815240B2/en active Active
- 2019-07-03 BR BR112020025701-0A patent/BR112020025701A2/pt unknown
- 2019-07-03 MX MX2020013896A patent/MX2020013896A/es unknown
- 2019-07-03 WO PCT/IB2019/055683 patent/WO2020008391A1/en active Application Filing
- 2019-07-03 EP EP19766356.0A patent/EP3817810A1/en active Pending
- 2019-07-03 IL IL279926A patent/IL279926B2/en unknown
- 2019-07-03 KR KR1020217003518A patent/KR102568464B1/ko active IP Right Grant
- 2019-07-04 JP JP2019124976A patent/JP7437646B2/ja active Active
-
2020
- 2020-09-29 US US17/036,849 patent/US11254684B2/en active Active
- 2020-12-16 MX MX2023006842A patent/MX2023006842A/es unknown
-
2021
- 2021-01-12 ZA ZA2021/00196A patent/ZA202100196B/en unknown
-
2022
- 2022-01-10 US US17/572,089 patent/US20220127274A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US10815240B2 (en) | 2020-10-27 |
CN112384282A (zh) | 2021-02-19 |
CA3105161A1 (en) | 2020-01-09 |
US20210009601A1 (en) | 2021-01-14 |
ZA202100196B (en) | 2022-09-28 |
KR20210029234A (ko) | 2021-03-15 |
EP3817810A1 (en) | 2021-05-12 |
WO2020008391A1 (en) | 2020-01-09 |
JP2020007308A (ja) | 2020-01-16 |
IL279926B2 (en) | 2023-12-01 |
TWI709562B (zh) | 2020-11-11 |
KR102568464B1 (ko) | 2023-08-21 |
AU2019299666A1 (en) | 2021-01-07 |
US20220127274A1 (en) | 2022-04-28 |
US11254684B2 (en) | 2022-02-22 |
IL279926B1 (en) | 2023-08-01 |
IL279926A (en) | 2021-03-01 |
JP7437646B2 (ja) | 2024-02-26 |
MX2020013896A (es) | 2021-03-09 |
BR112020025701A2 (pt) | 2021-03-16 |
TW202017929A (zh) | 2020-05-16 |
US20200123159A1 (en) | 2020-04-23 |
CA3105161C (en) | 2022-11-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2023006842A (es) | Proceso de fabricacion e intermediarios para un compuesto de pirrolo[2,3-d]pirimidina y su uso. | |
PH12019500930A1 (en) | PROCESS FOR THE PREPARATION OF PYRAZOLO[1,5-a]PYRIMIDINES AND SALTS THEREOF | |
PH12018500437A1 (en) | Novel pyrazolo [3,4-d] pyrimidine compounds or salt thereof | |
NZ766835A (en) | Pharmaceutical compounds | |
MX2021003241A (es) | Sal de tosilato de pirrolo[2,3-d]pirimidina, forma cristalina de la misma y proceso de fabricacion e intermediario al mismo. | |
MX2020003458A (es) | Derivados radiomarcados de un compuesto de 2-amino-6-fluoro-n-[ 5-fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3- carboxamida util como inhibidor de ataxia telangiectasia mutada y rad3 relacionado (atr) cinasa, preparacion de tal compuesto y diferentes formas solidas del mismo. | |
IL182893A0 (en) | PYRAZOLO-[1,5-a] PYRIMIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | |
TNSN06226A1 (en) | Pyrazolo[1,5-a]pyrimidin-7-yl-amine derivatives for use in the treatment of protein kinase dependent diseases | |
MX370390B (es) | Compuesto de 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]pirazolo[1, 5-a]pirimidin-3-carboxamida util como inhibidor de cinasa de ataxia telangiectasia mutada (atm) y rad3 relacionados (atr), su preparacion, diferentes formas solidas y sus derivados radiomarcados. | |
NZ604345A (en) | Pyrazolo[1,5-a]pyrimidines as antiviral agents | |
MY150059A (en) | Pyrrolo [2,3-d] pyrimidin derivatives as protein kinase b inhibitors | |
UA93375C2 (ru) | Ингибиторы протеинкиназ ha ochobe замещенных амидов | |
EA202091016A1 (ru) | Пиримидиновое соединение в качестве ингибитора jak киназы | |
MX2010006748A (es) | Pirazolo[1,5-a]pirimidinas utiles como inhibidores de jak2. | |
EP4302761A3 (en) | Crystalline forms of (s)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1h-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of making | |
SA519401322B1 (ar) | مركبات أريل كربوكساميد غير متجانسة كمثطبات لكيناز بروتين سيرين/ ثريونين متداخل مع المستقبل 2 | |
GEP20217327B (en) | Spirocycle compounds and methods of making and using same | |
EA202190323A1 (ru) | ИМИДАЗО[1,2-b]ПИРИДАЗИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ Trk | |
NZ754944A (en) | Imidazo [1,5-a] pyrazine derivatives as pi3kdelta inhibitors | |
MX2021012223A (es) | Compuestos de hexahidro-1h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria. | |
MX2020002630A (es) | Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta. | |
MX2021002042A (es) | Inhibidores de arginasa y sus metodos de uso. | |
MX2021008308A (es) | 3compuestos de fenilamidina 3-sustituida, preparacion y uso. | |
MX2020013847A (es) | Forma cristalina del compuesto para inhibir la actividad de cdk4/6 y uso del mismo. | |
MX2018009912A (es) | Proceso para preparar compuestos de 7h-pirrolo[2,3-d]pirimidina. |